Neuraly has claimed that it has dosed the first patient of NLY01 in its Phase 2 study for Parkinson’s disease.

Nature Medicine claimed in its study that NLYO1 tends to bind upregulated GLP-1R and blocks microglia’s pathological activation in animal models of disease such as Parkinson’s. Moreover, the study is believed to have revealed that NLYO1 averted death of neuronal cell and safeguarded against the decline of motor function following the derailment of pro-inflammatory cytokine products and glial activation.

President and CEO of Neuraly Seulki Lee highlighted that the present therapies meant for Parkinson’s disease offer merely temporary symptomatic enhancement and do not derail or stop the disease’s continuous surge.

He went on to signify the relevance of the Phase 2 study which is a stepping stone in the advancement of NLYO1 which will be a highly anticipated therapy for patients of Parkinson’s disease.

NLYO1 was tolerated in the Phase 1 study as it provided therapeutic doses with almost relentless exposure with once-in-a-week dose. Besides, NLYO1’s half-life was said to be around 12 and a half days and provided monitored weekly, attained 3-fold higher levels vis-à-vis shorter-acting GLP-1R agonists that are confined by downsides.

It is believed that the Phase 2 clinical trial will enroll around 240 patients in North America, including the U.S. and Canada. For the uninitiated, the Phase 2 clinical trial is a randomized, multicenter, placebo-controlled and double-blind trial. The trial is expected to analyze the efficacy, tolerability and safety of NLYO1 in cases with early Parkinson’s disease.

Neuraly’s Chief Scientific Officer of Neuraly Viktor Roschke expressed his delight at starting the Phase 2 study and stressed that their endeavor towards the treatment of the Parkinson’s disease and pre-empt the dip in function which is observed with prevalent therapies.

Source credit:

https://pipelinereview.com/index.php/2020030373936/Proteins-and-Peptides/Neuraly-Announces-First-Patient-Dosed-in-Phase-2-Clinical-Trial-of-NLY01-for-Patients-with-Parkinsons-Disease.html